Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7274660 | 0.86 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL118187 | 0.86 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL102137 | 0.86 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL3033258 | 0.86 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL12119842 | 0.86 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL23530875 | 0.86 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL25262974 | 0.85 | GAA (0.73) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL118407 | 0.85 | GAA (0.73) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL8608783 | 0.83 | GAA (0.71) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL8610256 | 0.83 | GAA (0.71) | GAACYP1A2KDM4EPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9018208-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018208-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9018208-B2 | Heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-8883826-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-11-11 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2011075643-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2178373-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Icagen, Inc. (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009026254-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026254-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062290-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | GAA 1268/4885CYP1A2 4029/4885KDM4E 1373/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | GAA 2249/4885CYP1A2 3019/4885KDM4E 1986/4885 |
| US-20100240663-A1 | HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK2, KCNK17 | GAA 1268/4885CYP1A2 4029/4885KDM4E 1373/4885 |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | CDK1, CDK3, CDK2 | GAA 2363/4885CYP1A2 3707/4885KDM4E 1443/4885 |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R5 | GAA 883/4885CYP1A2 1693/4885KDM4E 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.